The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

COMBINED DRUG THERAPY OF CHRONIC SCHIZOPHRENICS

Controlled Evaluation of Placebo, Dextro-Amphetamine, Imipramine, Isocarboxazid and Trifluoperazine Added to Maintenance Doses of Chlorpromazine
Published Online:https://doi.org/10.1176/ajp.117.11.997

Five hundred and twenty chronic, withdrawn and apathetic schizophrenic men were selected for 20 weeks of treatment with combined drug therapy. All had been on maintenance doses of chlorpromazine (200-600 mg.) for 2 or more months. Activator drugs were added to chlorpromazine adlibidum in the following maximum daily dosage (or less): dextro-amphetamine, 60 mg.; isocarboxazid and trifluoperazine, 30 mg.; imipramine, 225 mg.; and placebo.

Prior to the study and after 4 and 20 weeks of treatment, 462 patients were rated on 17 measures from an interview scale (IMPS) and a ward scale (PRP). Changes after 4 weeks of combined drugs were not impressive. At the end of 20 weeks, every treatment group except dextro-amphetamine improved, including the chlorpromazine-placebo group. None of the drug combinations was superior to chlorpromazine and placebo. Adding dextro-amphetamine increased hostile and paranoid belligerency and thinking disturbance.

Only 5% of the patients were dropped from the study because of side effects or complications. Abnormal laboratory tests were also infrequent and evenly distributed among the treatment groups. Trifluoperazine added to chlorpromazine increased the prevalence of extra-pyramidal syndromes, while dextro-amphetamine produced appetite and weight loss. All other treatment groups gained weight, significantly more from adding imipramine and isocarboxazid than from adding trifluoperazine or placebo.

Although the present study did not demonstrate substantial benefit from combined drug therapy, the chronicity of the patients and the method of drug administration limit generalization.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.